Mitsubishi UFJ Morgan Stanley Securities’s AstraZeneca AZN Stock Holding History

Mitsubishi UFJ Morgan Stanley Securities’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$66.9K	Sell	353 -669	-65%	-$126K	0.2%	98
2026 Q1	$202K	Buy	+1,022	New	+$197K	0.5%	53
2014 Q4	–	Sell	-570	Closed	-$41K	–	280
2014 Q3	$41K	Buy	+570	New	+$41.7K	0.12%	70

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Mitsubishi UFJ Morgan Stanley Securities's AZN Position: Q2 2026 in Review

Mitsubishi UFJ Morgan Stanley Securities reduced its AstraZeneca (AZN) stake by 65% in Q2 2026, selling an estimated $126K and leaving 353 shares worth $66.9K. The position accounts for 0.2% of the portfolio, ranked #98.

Mitsubishi UFJ Morgan Stanley Securities first reported a position in AZN in Q3 2014 and has held it in 3 quarters since. The position peaked at $202K in Q1 2026. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Mitsubishi UFJ Morgan Stanley Securities held 353 shares of AstraZeneca worth $66.9K as of Q2 2026.
Mitsubishi UFJ Morgan Stanley Securities sold 669 AstraZeneca shares in Q2 2026, an estimated $126K.
AstraZeneca made up 0.2% of Mitsubishi UFJ Morgan Stanley Securities's portfolio in Q2 2026, its #98 holding.
Mitsubishi UFJ Morgan Stanley Securities first reported a position in AstraZeneca in Q3 2014 and has held it in 3 quarters since.
Mitsubishi UFJ Morgan Stanley Securities's AstraZeneca position peaked at $202K in Q1 2026.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Mitsubishi UFJ Morgan Stanley Securities's 13F filing for Q2 2026, filed 15 Jul 2026.